会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • 피롤로피리미디논 유도체의 헤미타르트레이트 염 및 이의제조방법
    • 吡咯烷二酮衍生物的制备方法及其制备方法
    • KR1020080003604A
    • 2008-01-08
    • KR1020060062048
    • 2006-07-03
    • 에스케이케미칼주식회사
    • 김재선김남호이진영이남규이윤정장우제윤원노오준교성진흥엄기안
    • C07D487/04
    • A hemitartrate of pyrrolopyrimidinone derivative as a PDE5(phosphodiesterase 5) inhibitor is provided to satisfy physicochemical conditions suitable as a pharmaceutically acceptable salt including low hygroscopicity, suitable solubility, low adhesive properties of tablet, improved stability and convenient mass production. A hemitartrate of pyrrolopyrimidinone derivative represented by the formula(1) is prepared by preparing tartaric acid-containing reaction solution by solubilizing 0.5-20 wt.% of tartaric acid in water or organic solvent, mixing the tartaric acid-containing reaction solution with SK-3530 free base represented by the formula(3) as pyrrolopyrimidinone derivative, mixing and reacting the mixture to obtain a solid, and filtering, washing and drying the solid at -30 to 50 deg.C. A pharmaceutical formulation for preventing and treating diseases associated with PDE5 comprises the hemitartrate of pyrrolopyrimidinone derivative represented by the formula(1), wherein the daily dosage of hemitartrate of pyrrolopyrimidinone derivative is 10.0-200.0 mg/kg.
    • 提供了作为PDE5(磷酸二酯酶5)抑制剂的吡咯并嘧啶酮衍生物的半盐酸盐以满足适合作为药学上可接受的盐的物理化学条件,包括低吸湿性,适合的溶解性,片剂的低粘合性,改进的稳定性和方便的批量生产。 通过将0.5〜20重量%的酒石酸在水或有机溶剂中溶解制备含酒石酸的反应溶液,将含酒石酸的反应溶液与SK-型反应溶液混合,制备由式(1)表示的吡咯并嘧啶酮衍生物的半盐酸盐, 3530由式(3)表示的游离碱作为吡咯并嘧啶酮衍生物,混合并使混合物反应得到固体,并在-30至50℃过滤,洗涤和干燥固体。 用于预防和治疗与PDE5相关的疾病的药物制剂包含由式(1)表示的吡咯并嘧啶酮衍生物的酒石酸盐,其中吡咯并嘧啶酮衍生物的酒石酸盐的日剂量为10.0-200.0mg / kg。
    • 9. 发明公开
    • 피롤로피리미디논 유도체의 시트레이트 염 및 이의제조방법
    • 吡咯啉二酮衍生物的化学和制备方法
    • KR1020080003601A
    • 2008-01-08
    • KR1020060062043
    • 2006-07-03
    • 에스케이케미칼주식회사
    • 김재선김남호이진영이남규이윤정장우제윤원노오준교성진흥엄기안
    • C07D487/04
    • A citrate of pyrrolopyrimidinone derivative is provided to inhibit activity of PDE5(phosphodiesterase 5) and improve physicochemical properties including nonhygroscopicity, long-term storage and light and heat stability, so that the compound is useful for prevention and treatment of diseases associated with PDE5 such as impotence, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract symptom. A process for preparing a citrate of pyrrolopyrimidinone derivative represented by the formula(1) comprises the steps of: solubilizing or suspending citric acid represented by the formula(3) in a solvent selected from water, acetone, methanol, ethanol, isopropanol and acetonitrile to prepare citric acid solution containing 1-30 wt.% of citric acid; mixing the citric acid solution with pyrrolopyrimidinone derivative represented by the formula(2); and reacting the mixture at -30 to 50 deg.C, and filtering, washing and drying the solid product obtained from the reaction to form a crystalline acid addition salt.
    • 提供吡咯并嘧啶酮衍生物的柠檬酸盐以抑制PDE5(磷酸二酯酶5)的活性并改善物理化学性质,包括不吸湿性,长期储存和光热稳定性,使得该化合物可用于预防和治疗与PDE5相关的疾病,例如 阳ence,肺动脉高压,慢性阻塞性肺病,良性前列腺肥大及下尿路症状。 制备由式(1)表示的吡咯并嘧啶酮衍生物的柠檬酸盐的方法包括以下步骤:将由式(3)表示的柠檬酸溶解或悬浮在选自水,丙酮,甲醇,乙醇,异丙醇和乙腈的溶剂中,至 制备含有1-30重量%柠檬酸的柠檬酸溶液; 将柠檬酸溶液与式(2)表示的吡咯并嘧啶酮衍生物混合; 并将混合物在-30至50℃下反应,并过滤,洗涤和干燥从反应得到的固体产物,以形成结晶酸加成盐。